The latest news from academia, regulators
research labs and other things of interest
Posted: March 6, 2008
PrimeGen Biotech and Unidym Form an Alliance to Explore Carbon Nanotubes in Stem Cell Medicine
(Nanowerk News) PrimeGen Biotech LLC and Unidym Inc., a majority-owned subsidiary of Arrowhead Research
Corporation (NASDAQ:ARWR), announced a corporate alliance focused
on exploring new applications for carbon nanotubes in stem cell medicine.
Unidym brings to this partnership its leadership in carbon nanotube science,
technology and production. In a press release last week, PrimeGen announced at
the Stem Cell Summit meeting in New York City that Company researchers have, for the
first time, successfully used non-viral technologies to reprogram adult human cells into
stem cells that the Company refers to as intermediate iPS cells. Unlike embryonic stem
cells, induced pluripotent stem cells, or iPS cells, are derived directly from a patient’s
adult human tissues such as skin. PrimeGen will have access to Unidym’s extensive
patent portfolio, services and industry standard HIPCO® carbon nanotubes.
“We’re excited to bring together leaders in the field of nanotechnology materials
science with our talented team of stem cell researchers,” said Thomas C.K. Yuen, CEO,
PrimeGen Biotech. “Our combined efforts will undoubtedly generate important
advances in the field of regenerative medicine and bring us closer to the day when
clinically safe and effective individualized stem cell therapies can be administered in a
routine manner to patients.”
“PrimeGen’s innovative use of carbon nanotubes in cell reprogramming brings
nanotube technology into a truly ground breaking field of use,” said Art Swift, Unidym’s President and CEO. “Given Unidym’s extensive experience with carbon nanotubes and our foundational patent portfolio, this alliance uniquely leverages the
natural synergies between our companies. We look forward to helping PrimeGen
advance its breakthrough solution for stem cell production ultimately into clinical use as
a stem-cell based therapy.”
PrimeGen has submitted its scientific findings, as abstracts, for presentation at the
International Society of Stem Cell Research meeting to be held this year in Philadelphia,
June 11-14. Manuscripts are also being prepared for peer-reviewed publication.
About PrimeGen Biotech LLC
PrimeGen Biotech (www.primegenbiotech.com) is dedicated to the research and therapeutic
applications of adult stem cells, leading to individualized patient therapies. Entering its fifth year
of operations at the pre-clinical stage of product development, the company specializes in two
core technologies: germ line stem cells and therapeutic reprogramming. Pioneering work on
induced pluripotent stem cells (iPS cells), positions PrimeGen as a leader in moving this
breakthrough from research to therapy. Future applications of both PrimeGen core technologies
will enlist a patient’s own adult tissue cells to generate stem cells for regenerative and restorative
medical treatments. Based in Irvine, California, PrimeGen Biotech is a privately held, Delaware
limited liability company.
Unidym (www.unidym.com) is a leader in the manufacture and application of carbon nanotubes
(CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties.
Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide
range of customers and business partners. As a result of its recent merger with CNI, Unidym
possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing
and processing as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent
electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for
fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an
aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of
CNTs. Unidym’s licensing program, technical expertise and manufacturing facilities can enable
partners to rapidly develop CNT solutions for their specific applications.
Unidym is a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR).
About Arrowhead Research Corp.
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded
nanotechnology company commercializing new technologies in the areas of life sciences,
electronics, and energy. Arrowhead is building value for shareholders through the progress of
majority owned subsidiaries founded on nanotechnologies originally developed at universities.
The company works closely with universities to source early stage deals and to generate rights to
intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four
subsidiaries commercializing nanotech products and applications, including anti-cancer drugs,
RNAi therapeutics, carbon-based electronics and compound semiconductor materials.